Ubiquitination in apoptosis signaling
van de Kooij, L.W.

Link to publication

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
LIST OF PUBLICATIONS

van de Kooij B*, Rooswinkel RW*, Kok F, Herrebout M, de Vries E, Paauwe M, Janssen GMC, van Veelen PA and Borst J. Polyubiquitination and proteasomal turnover controls the anti-apoptotic activity of Bcl-B
*Oncogene 2013; 32(48): 5439-48

van de Kooij B*, Verbrugge I*, de Vries E, Gijsen M, Montserrat V, Maas C, Neefjes J and Borst J. Ubiquitination by the Membrane-Associated RING-CH-8 (MARCH-8) ligase controls steady-state cell surface expression of Tumor Necrosis Factor-related Apoptosis Inducing Ligand (TRAIL) Receptor 1
*J Biol Chem 2013; 288(9): 6617-28

van de Kooij B, de Vries E, Rooswinkel RW, Janssen GMC, van Veelen PA and Borst J. The N-end rule ligase UBR2 interacts with the N-terminal fragment of caspase-cleaved Bid and targets it for ubiquitination
*Manuscript in preparation

van de Kooij B, Rooswinkel RW, de Vries E*, Janssen GMC*, Kok F, van Veelen PA and Borst J. N-terminal acetylation stabilizes proteins by blocking N-terminal ubiquitination, and by directly inhibiting proteasomal processing
*Submitted for publication

*Accepted for publication in Blood

Rooswinkel RW, van de Kooij B, Verheij M, Borst J. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
*Cell Death Dis 2012;3:e366

Maas C, Verbrugge I, de Vries E, Savich G, van de Kooij B, Tait SW, Borst J. Smac/DIABLO release from mitochondria and XIAP inhibition are essential to limit clonogenicity of Type I tumor cells after TRAIL receptor stimulation.
*Cell Death Differ 2010; 17(10), 1613-23

* These authors contributed equally